Apexigen, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own2.90% Shs Outstand22.57M Perf Week-30.05%
Market Cap30.35M Forward P/E- EPS next Y-1.51 Insider Trans0.00% Shs Float20.71M Perf Month-43.20%
Income-4.20M PEG- EPS next Q-0.49 Inst Own28.10% Short Float / Ratio0.08% / 0.16 Perf Quarter-72.85%
Sales- P/S- EPS this Y- Inst Trans79.36% Short Interest0.02M Perf Half Y-86.00%
Book/sh6.78 P/B0.21 EPS next Y19.70% ROA-4.90% Target Price13.00 Perf Year-85.74%
Cash/sh0.00 P/C303.45 EPS next 5Y- ROE-5.10% 52W Range1.54 - 31.35 Perf YTD-85.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-95.47% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low-7.79% ATR0.28
Employees22 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)25.18 Volatility13.35% 13.63%
OptionableYes Debt/Eq0.02 EPS Q/Q-536.90% Profit Margin- Rel Volume0.29 Prev Close1.57
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume104.45K Price1.42
Recom2.00 SMA20-32.31% SMA50-43.99% SMA200-81.82% Volume30,754 Change-9.55%
Nov-15-22 08:00AM
Nov-14-22 07:00AM
Nov-11-22 08:00AM
Oct-17-22 03:58PM
Sep-12-22 08:38AM
08:00AM Loading…
Sep-10-22 08:00AM
Sep-07-22 08:01AM
Sep-05-22 08:00AM
Aug-31-22 06:25PM
Aug-08-22 08:43AM
Aug-04-22 08:00AM
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.